OLF与DCF方案治疗晚期胃癌的临床观察

目的观察OLF方案和DCF方案治疗晚期胃癌的近期疗效、疾病控制率及毒副反应。方法一组采取OLF方案奥沙利铂(L-OHP)130 mg.m-2静脉滴注2 h,第1天;亚叶酸钙(CF)200 mg.m-2,静脉滴注2 h,第1～5天;氟尿嘧啶(5-Fu)500 mg.m-2,静脉滴注6 h,第1～5天,每3周为1个周期,另外一组采取DCF方案多西紫杉醇75 mg.m-2静脉滴注,第1天;氟尿嘧啶(5-Fu)500 mg.m-2,泵滴120 h,顺铂(DDP)25 mg.m-2静脉滴注,第1～3天。结果 DCF组和OLF组中疾病控制率分别为58.3%(21/36)和56.7%(17/30),两者比较意义无统计学差异(P0.05)。但DCF组在血液毒性及消化道反应方面较OLF组发生率高。结论 OLF和DCF方案在晚期胃癌化疗中疾病控制率无明显差异,但OLF与DCF相比,OLF方案在化疗毒副反应和经济方面更易被患者接受。

A clinical observation of OLF and DCF in the treatment of advanced gastric cancer

Objective To observe the efficacy,disease control rate and toxicity of OLF and DCF for the patients with advanced gastric cancer.Methods For OLF group oxaliplatin 130 mg·m-2,intravenous infusion dl,calcium folinate 200 mg·m-2,intravenous infusion 1~5 d,5-fluorouraeil 500 mg·m-2,intravenous infusion 1~5 d,every three weeks.For DCF group Docetaxel 75 mg·m-2,intravenous infusion d1;5-fluorouraeil 500 mg·m-2 ntravenous injection/120 h;Cisplatin,25 mg·m-2,intravenous infusion dl-3.Results The disease control rate of two groups were 58.3%（21/36）and 56.7%（17/30）,with no statistical significance between the two groups（P0.05）.Compared with OLF group,the toxicity in the blood and digestive tract reaction of DCF group had the high incidence.Conclusion The disease control rate has no significant difference between the two groups in advanced gastric cancer,but compared with the DCF group,the toxicity and economic aspect of the OLF can be accepted more easily.